Terpenoids as Potential Anti-Alzheimer’s Disease Therapeutics
AbstractAlzheimer’s disease (AD) is one of the most well-known neurodegenerative diseases and explains 50–60% of dementia in patients. The prevalence rate of AD is positively correlated with age and AD affects ≥ 40% of those over 85 years old. The major AD therapeutics available on the market are acetylcholinesterase inhibitors, such as tacrine and donepezil. New therapeutic agents that can block the disease-inducing mechanisms are essential. Diverse efforts have been made to discover anti-AD agents from natural sources. In this review article, we describe some representative terpenoids such as ginsenosides, gingkolides, and canabinoids as potential anti-AD agents. These compounds exhibit promising in vitro and in vivo biological activities, but are still waiting clinical trials. Additionally, we also discuss some terpenoids including cornel iridoid glycoside, oleanolic acid, tenuifolin, cryptotanshinone, and ursolic acid, which are under investigation for their in vitro and in vivo animal studies.
Share & Cite This Article
Yoo, K.-Y.; Park, S.-Y. Terpenoids as Potential Anti-Alzheimer’s Disease Therapeutics. Molecules 2012, 17, 3524-3538.
Yoo K-Y, Park S-Y. Terpenoids as Potential Anti-Alzheimer’s Disease Therapeutics. Molecules. 2012; 17(3):3524-3538.Chicago/Turabian Style
Yoo, Ki-Yeol; Park, So-Young. 2012. "Terpenoids as Potential Anti-Alzheimer’s Disease Therapeutics." Molecules 17, no. 3: 3524-3538.